Investors

Expedeon Appoints Steve Howell as Non-Executive Director

Cambridge, UK, 01 February 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the appointment of Professor Steve Howell to the Board of Directors.

Steve has over 20 years of experience building and growing life science enterprises, including founding life science investment company Innova Partnerships in 2006. Prior to this he was Director of Business Development at Alere Inc, and Research Director at Unipath Ltd, after joining Unilever Plc. Steve is currently a non-executive director of Reminova Ltd and Relaymed. He is visiting Professor of Commercial Innovation at Kings College London and also advises the Scottish and Irish governments on high growth businesses and life science strategy.
Tim Bernard, Chairman of the Board at Expedeon, commented: “We are delighted to welcome Steve to the Board of Directors. His knowledge and experience will be a valuable addition to the company as we continue to expand.

Professor Howell said: “Expedeon’ world leading bioconjugation technology business is backed by a team of dedicated executives, scientists and customer service personnel. I am very pleased to be joining the Board, to help lead Innova through its next stages of development.”